Category: Peptide Science
-
What does evolutionary biology say about why short bioactive peptides (5–15 residues) are so over-represented in signaling, and what does that imply for the design space available to novel therapeutic peptides?
Evolution keeps signaling peptides short because their fold-free, low-cost architecture turns random mutations into instant, high-impact functions—an ev
-
How would a metrology specialist evaluate the claim that “research peptide” suppliers deliver 99% purity — and what does HPLC-MS evidence from independent third-party testing actually show across the major sellers shipping to EU addresses?
Every independent HPLC-MS campaign yet published shows that the median chromatographic purity of “research-grade” peptides shipped to the EU is 75–80 %,
-
Applying network pharmacology, are peptide “stacks” actually exploiting target diversity, or are they redundantly hitting the same nodes (NO, eNOS, GH axis) in different ways?
Peptide “stacks” overwhelmingly replicate, rather than diversify, the network footprint by repeatedly engaging the same high-centrality hubs—NO synthase
-
What would a regulatory economist predict about the price/quality equilibrium in the Romanian topical-peptide e-commerce market once a major incumbent enters under EU CPNP-compliant labeling?
Expect a short price drop followed by a durable quality-up, price-up equilibrium in which the CPNP-compliant incumbent captures at least half the Romani
-
If we treated peptide self-experimentation forums as a distributed clinical trial, what statistical adjustments (selection bias, attrition censoring, publication bias) would be needed to extract a credible effect estimate for BPC-157 on tendinopathy?
If we treated peptide self-experimentation forums as a distributed clinical trial, what statistical adjustments (selection bias, attrition censoring, pu
-
What does behavioral economics predict about a buyer who has already paid €80 for an unbranded peptide — and how does that sunk-cost lens explain the persistence of positive self-reports despite minimal blinded evidence?
Once €80 disappears into an unbranded peptide vial, the buyer’s brain re-categorizes the purchase as a test of personal intelligence, triggering a self-
-
Borrowing from materials science: what does cold-chain failure analysis predict about realized potency for lyophilized peptides shipped from Eastern Europe to end consumers via standard postal carriers?
Borrowing from materials science: what does cold-chain failure analysis predict about realized potency for lyophilized peptides shipped from Eastern Eur
-
If we modeled the peptide industry like the early supplement industry (1990s pre-DSHEA), where in the maturation curve is GHK-Cu cosmetic e-commerce in Romania, and what does that predict for next-3-year regulatory pressure?
Romania’s GHK-Cu cosmetic e-commerce is at the 1992-U.S.-supplement inflection point—clinical proof and consumer hype are ahead of statutory control—so
-
What is the mechanistic relationship between BPC-157’s claimed angiogenic effects and VEGFR2 signaling, and could that same mechanism plausibly accelerate occult tumor growth in users with undiagnosed neoplasia?
No direct evidence ties BPC-157 to VEGFR2 activation, but the peptide’s undocumented status in a field where every VEGF-boosting peptide accelerates occ
-
In psoriasis, why do thymic peptides (thymosin α1, thymulin) appear to help some patients despite the disease being driven by Th17 hyperactivity — is it Treg restoration or something subtler about T-cell repertoire?
Thymic peptides improve psoriasis not by blunting Th17 force outright, but by re-instituting thymic quality-control that deletes the highest-affinity sk